Curi RMB Capital LLC Acquires 715 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Curi RMB Capital LLC lifted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 9.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,616 shares of the company’s stock after acquiring an additional 715 shares during the period. Curi RMB Capital LLC’s holdings in Vaxcyte were worth $705,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. CIBC Asset Management Inc lifted its stake in shares of Vaxcyte by 5.5% during the 4th quarter. CIBC Asset Management Inc now owns 3,307 shares of the company’s stock worth $271,000 after acquiring an additional 171 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after buying an additional 260 shares in the last quarter. Catalyst Funds Management Pty Ltd lifted its holdings in Vaxcyte by 1.7% during the fourth quarter. Catalyst Funds Management Pty Ltd now owns 18,400 shares of the company’s stock worth $1,506,000 after buying an additional 300 shares during the period. Whipplewood Advisors LLC bought a new stake in Vaxcyte during the 4th quarter valued at $28,000. Finally, Blue Trust Inc. boosted its position in Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after acquiring an additional 371 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Activity

In other news, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $86.22, for a total value of $689,760.00. Following the completion of the transaction, the chief operating officer now owns 205,695 shares of the company’s stock, valued at $17,735,022.90. The trade was a 3.74 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 32,000 shares of company stock valued at $2,638,800 in the last ninety days. Insiders own 3.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Evercore ISI upgraded Vaxcyte to a “strong-buy” rating in a research note on Monday, March 31st. The Goldman Sachs Group decreased their price target on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Guggenheim restated a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. Finally, Bank of America reduced their price target on Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Vaxcyte presently has an average rating of “Buy” and a consensus target price of $136.50.

Vaxcyte Stock Performance

Shares of PCVX opened at $30.65 on Monday. The stock has a 50-day moving average of $60.72 and a two-hundred day moving average of $82.64. The stock has a market cap of $3.95 billion, a P/E ratio of -6.66 and a beta of 1.26. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.14. Analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.